Skip to content
Screener

Pre-Tax Income at other companies

Amgen logo
AmgenAMGN
$2.77B+76.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.53B+0.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$632.79M-387%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$74.03M-34.0%
CTO
Citius Oncology, Inc.CTOR
-$26.84M-259%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$74.9M-96.9%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.48B+539%
Enterprise value$2.56B+435%
P/S44.6×+39.4×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemThree Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31,
Interest income4,2422,874
Other income (expense), net (including income of $2 and $321 for the three months ended March 31, 2026 and 2025, respectively, from a related party)(336)266
Total non-operating income (expense), net(4,036)(1,834)
Loss before provision for income taxes and equity method investment(43,090)(46,369)
Provision for income taxes6452
Loss before equity method investment(43,154)(46,421)
Loss from equity method investment(1,750)(4,461)
Net loss$$$(44,904)(50,882)

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's pre-tax income?
Nektar Therapeutics (NKTR) reported pre-tax income of -$43.09M in Q1 2026.
How has Nektar Therapeutics's pre-tax income changed year-over-year?
Nektar Therapeutics's pre-tax income increased by 7.1% year-over-year, from -$46.37M to -$43.09M.
What is the long-term trend for Nektar Therapeutics's pre-tax income?
Over 4 years (2021 to 2025), Nektar Therapeutics's pre-tax income has grown at a -26.2% compound annual growth rate (CAGR), from -$523.28M to -$155.49M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Nektar Therapeutics's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude